

Executive Summary Of the Minutes Board of Directors' Meeting January 19-20, 2012

Proceedings:

Meeting Called to Order at 8:00 a.m. (local time) by Chair, Rebecca A. Lewis, Esquire. A quorum was noted.

Proclamation of Appreciation - Chair presented to Robert L. Baitty for his service on the board upon his retirement from (HRSA) Health Resources and Services Administration.

Minutes from Sept. 22-23, 2011 Board meeting were reviewed and approved with no substantive changes.

Board Resolution was presented to approve the placement of Subramanian Krishnan as an NMDP Corporate Officer. Mr. Krishnan, Chief Financial Officer, was approved unanimously.

Update from Chief Executive Officer:

- Celebrating the NMDP's 25th Anniversary and the 50,000th Transplant throughout 2012.
- *HapLogicSM III* implemented mid-December, 2011. The conversion improves the accuracy of finding a match, speeding up the search process.
- 171 Network Recruiters attended the RCD National Meeting in Minneapolis in conjunction with the Annual Council meeting. Training, focusing on recruiting donors aged 18-44 years, was conducted.
- Donor Compensation Lawsuit– A *decision* on Dec. 1, 2011 by the 9th District Court that PBSC donors can be compensated as the product is different from bone marrow-challenges the National Organ Transplant Act. The Department of Justice is expected to respond to the District Court's decision.
- Presentation on FedEx *SenseAware* process to ship products domestically.
- Compliance Oversight Committee met in December. No material compliance deficiencies were identified.

Chief Financial Officer's Report - The Board reviewed the financial summary as of December 31, 2011.

Network Approvals - Recommendations from the Membership Review Committee for *network center* changes since the Sept. 22-23, 2011 Board meeting were reviewed and unanimously approved.

CIBMTR released findings of a recent study entitled "The Effect of Donor Age on Transplant Outcomes." The results show that older donors with no mismatch and a younger donor with a single mismatch provide the same outcome for the patient. The study also proved that an ABO blood type mismatch is a risk for the patient.

Strategic Planning - Key strategic initiatives: International Activity; New Revenue Sources; Cost - Recovery.

Deloitte Audit - The Audit Committee reviewed and approved the external audit report prepared by Deloitte. No significant findings were noted. A summary of the external audit was made available to interested board members.

Next meeting - Thursday & Friday, June 7-8, 2012 – Portland, Oregon.

Meeting Adjourned